



## ANALYSIS OF A FRACTIONAL ORDER MATHEMATICAL MODEL FOR TUBERCULOSIS WITH OPTIMAL CONTROL

RUIQING SHI\*, JIANING REN, CUIHONG WANG

School of Mathematics and Computer Science, Shanxi Normal University, Linfen 041000, China

**Abstract.** In this paper, a fractional-order mathematical model with control is constructed to describe the transmission of tuberculosis. Two cases are considered: the constant control and the optimal control. In the former case, the stability conditions of the disease-free equilibrium and the endemic equilibrium are obtained. In the second case, optimal control theory is applied to the corresponding model. The optimal control formula is derived by use of the Hamiltonian function and the Pontryagin's Maximum Principle. In addition, some numerical simulations are performed to support our analytic results.

**Keywords.** Fractional order; Tuberculosis; Basic reproduction number; Stability; Optimal control.

### 1. INTRODUCTION

Tuberculosis is an infectious respiratory disease caused by mycobacterium tuberculosis. Despite advances in technology, tuberculosis (TB) remains one of the world top 10 causes of death. Recent data suggest that the global incidence of TB is rising, and this is mainly because of its association with the human immunodeficiency virus (HIV) [1]. In 2017, 10 million people were infected with TB, and 1.6 million died from the disease (including 0.3 million with HIV). Ending the TB epidemic by 2030 is among the health targets of the Sustainable Development Goals [2].

The human immune response limits the proliferation of bacteria after the initial infection. As a result, most infected people remain latent throughout their lives, with about 10% of those infected eventually developing active TB. The average incubation period (non-infectious) for TB can range from a few months to several decades [3]. Because of treatment and prevention methods are so different, it is critical to accurately classify the TB situation. Tuberculosis, of course, can be treated with drugs [4]. But most high-incidence patients also use only existing TB vaccines, Calmette-Guérin. And its effectiveness in preventing TB is controversial [5]. In recent years, treatment has become difficult due to the emergence of drug-resistant strains of

\*Corresponding author.

E-mail addresses: shirq1979@163.com (R. Shi), 1967817314@qq.com (J. Ren).

Received November 29, 2019; Accepted April 6, 2020.

Mtb [6, 7]. The cure rate of ordinary tuberculosis patient is more than 90%. However, the cure rate of multidrug resistant tuberculosis patient is only about 50%, and the treatment cycle is as long as 18-24 months [2]. So, in addition to controlling TB in terms of treatment, it needs to be controlled in other ways.

Recently, the theoretical analysis of fractional differential equations and the study of numerical methods have become the focus of people's attention. Fractional calculus is a method to extend the classical integral order calculus to real or complex order [8, 9, 10, 11, 12]. Fractional derivative is a good mathematical tool to describe the memory and genetic characteristics of complex systems [13]. At present, there are more than six definitions of fractional derivative, among which Riemann-Liouville and Caputo derivatives are the most commonly used [14]. As we all know, in the case of time fractional Caputo derivative, the initial conditions are expressed by the values of the unknown function and its integer derivative with clear physical meaning [15]. So, we will adapt the Caputo's definition in our paper. In recent years, fractional differential equations also have been widely used in physics, chemistry, electricity, biology, economics, epidemiology and other fields [16, 17, 18, 19, 20].

It is known that mathematical models play a crucial role in many dynamics and control, including epidemics of malaria and tuberculosis [21, 22, 23, 24, 25]. Moreover, the enormous public health burden of TB requires the use of mathematical models to understand the dynamics of transmission and to identify effective control strategies. Particularly, in [26], Sweilam and Mekhlafi studied optimal control for fractional general nonlinear multi-strain tuberculosis model. The results show that the fractional-order model can describe more complex dynamical processes than the integer model, and can easily include memory effects that exist in the real world. In recent years, more and more scholars studied the optimal control of fractional order, for example [27, 28, 29, 30]. The aim of this paper is to investigate the best control methods to minimize the number of active, infectious and latent TB patients, taking into account the cost of treating TB patients.

Recently, Liu and Zhang [31] investigated the following tuberculosis model:

$$\left\{ \begin{array}{l} \frac{dS}{dt} = \Lambda - \beta S(I + \rho_1 T) - (\mu + p)S, \\ \frac{dV}{dt} = pS - \rho_2 \beta V(I + \rho_1 T) - \mu V, \\ \frac{dL}{dt} = l\beta S(I + \rho_1 T) + \rho_2 \beta V(I + \rho_1 T) - (\mu + \delta)L + \rho T, \\ \frac{dI}{dt} = (1 - l)\beta S(I + \rho_1 T) + \delta L - (\mu + \varepsilon + \gamma)I, \\ \frac{dT}{dt} = \gamma I - (\mu + \rho)T, \\ N(t) = S(t) + V(t) + L(t) + I(t) + T(t). \end{array} \right. \quad (1.1)$$

In the model above, the incidence rate was bilinear. Incidence is a very important factor in infectious disease models, the most commonly used contact rate are bilinear incidence and standard incidence. Between these two contact rates, there is a more realistic saturation contact rate [32, 33]. Because it contains behavioral changes and population effects of infected individuals, the unbounded exposure rate can be prevented by selecting appropriate parameters. Saturation rates were used in many epidemic models; see, for example, [34, 35].

Thus, based on the integer order tuberculosis model (1.1), we put forward an improved fractional order tuberculosis infection model with saturating incidence rate as follows:

$$\begin{cases} D^\alpha S(t) = \Lambda - \frac{\beta SI}{1 + \theta_1 I} - \rho_1 \beta ST - (\mu + p)S, \\ D^\alpha V(t) = pS - \frac{\rho_2 \beta VI}{1 + \theta_2 I} - \rho_1 \rho_2 \beta VT - \mu V, \\ D^\alpha L(t) = \frac{l \beta SI}{1 + \theta_1 I} + \rho_1 l \beta ST + \frac{\rho_2 \beta VI}{1 + \theta_2 I} + \rho_1 \rho_2 \beta VT - (\mu + \delta)L + \rho T, \\ D^\alpha I(t) = \frac{(1-l)\beta SI}{1 + \theta_1 I} + (1-l)\rho_1 \beta ST + \delta L - (\mu + \varepsilon + \gamma)I, \\ D^\alpha T(t) = \gamma I - (\mu + \rho)T, \end{cases} \quad (1.2)$$

where  $\rho_1 < 1$ , and  $\rho_2 < 1$ . Obviously, the biologically feasible region of the above system (1.2) is

$$\Omega = \left\{ (S, V, L, I, T) \in R_+^5 : S \leq \frac{\Lambda}{\mu + p}, V \leq \frac{\Lambda p}{\mu(\mu + p)}, N \leq \frac{\Lambda}{\mu} \right\}.$$

In Eq. (1.2)  $D^\alpha$  ( $0 < \alpha < 1$ ) denotes Caputo fractional differential operator, and the model are based on the following scenarios:

(H1)  $S(t)$ ,  $V(t)$ ,  $L(t)$ ,  $I(t)$  and  $T(t)$  represent susceptible population, vaccinated population, population infected with TB in latent (asymptomatic) stage, population infected with TB in the active stage and treated population infected with TB, respectively.

(H2) We assumed that vaccinated individuals could also be infected.

(H3) We assumed that that treated individuals also had the ability to infect others during treatment.

(H4) Due to drug resistance, reinfection may also occur after treatment and enter the incubation period.

The descriptions of parameters are listed in Table 1, and some parameter values are take from [36, 37, 38].

TABLE 1. Description of the parameters for system (1.2)

Parameters	Description	Default value
$\Lambda$	the recruitment of the susceptible class	1428 person year <sup>-1</sup>
$\beta$	the disease transmission coefficient	(0, 1)
$\rho_1$	the infectiousness among individuals with active TB who are treated	0.25
$\rho_2$	the reduction in risk of infection due to vaccination	(0, 1)
$\mu$	the natural death rate	0.014 year <sup>-1</sup>
$l$	susceptible individuals who acquire infection and move to latent TB class	(0, 1)
$\delta$	the rate of individuals leave class $L$ for class $I$	(0, 1)
$\varepsilon$	the death rate due to disease	(0.1, 1)
$p$	the vaccination rate	(0, 1)
$\rho$	the rate of successfully treated individuals and return to latent TB class	(0.1, 1)
$\gamma$	the rate of infectious individuals who are treated	(0, 1)
$\theta_1, \theta_2$	half-saturation constant	(0,1)

The paper is organized as follows. In Section 2, we introduce some definitions and lemmas for fractional-order differential equations. In Section 3, we study the existence and stability

of equilibrium points and numerical simulations. In Section 4, we present the formulation of the optimal control problems and investigate the existence of an optimal control function and derive an optimal system characterizing the optimal control and numerical simulations. In the last section, Section 5, some conclusions and discussions are provided.

## 2. PRELIMINARIES

For convenience, we list some of the basic definitions and lemmas of the fractional calculus. In fractional-order calculus, there are many fractional-order integration and fractional-order differentiation that have been defined, for example, the Grunwald-Letnikov (GL) definition, the Riemann-Liouville (RL) definition and the Caputo definition. Since the initial condition is the same as the form of integral differential equation, we will adopt the definition of Caputo in this paper.

**Definition 2.1.** [15] The Riemann-Liouville fractional integral of order  $\alpha > 0$  for a function  $f : R^+ \rightarrow R$  is defined by

$${}_0D_t^{-\alpha} f(t) = \frac{1}{\Gamma(\alpha)} \int_0^t (t-s)^{\alpha-1} f(s) ds, \quad t \geq 0.$$

Based on this definition of Riemann-Liouville fractional integral, the fractional-order derivative in Riemann-Liouville sense and Caputo sense are given below.

**Definition 2.2.** [15] The Riemann-Liouville fractional derivative of order  $\alpha > 0$  for a function  $f : R^+ \rightarrow R$  is defined by

$${}^RL D_t^\alpha f(t) = \frac{d^k}{dt^k} ({}_0D_t^{-(k-\alpha)} f(t)) = \frac{1}{\Gamma(k-\alpha)} \frac{d^k}{dt^k} \int_0^t (t-s)^{k-\alpha-1} f(s) ds, \quad t \geq 0,$$

where  $k-1 \leq \alpha < k$ ,  $k \in N$  and  $\Gamma(\cdot)$  is the Gamma function, that is,

$$\Gamma(\alpha) = \int_0^{+\infty} t^{\alpha-1} e^{-t} dt.$$

In particular, if  $0 < \alpha < 1$ , then

$${}^RL D_t^\alpha f(t) = \frac{1}{\Gamma(1-\alpha)} \frac{d}{dt} \int_0^t (t-s)^{-\alpha} f(s) ds.$$

**Definition 2.3.** [15] The Caputo fractional derivative of order  $\alpha > 0$  for a function  $f : R^+ \rightarrow R$  is defined by

$${}_0^C D_t^{-\alpha} f(t) = {}_0D_t^{-(k-\alpha)} f^{(k)}(t) = \frac{1}{\Gamma(k-\alpha)} \int_0^t (t-s)^{k-\alpha-1} f^{(k)}(s) ds, \quad t \geq 0,$$

where  $k-1 \leq \alpha < k$ ,  $k \in N$  and  $f^{(m)}(t)$  is the m-order derivative of  $f(t)$ . In particular, if  $0 < \alpha < 1$ , then

$${}_0^C D_t^{-\alpha} f(t) = \frac{1}{\Gamma(1-\alpha)} \int_0^t \frac{f'(s)}{(t-s)^\alpha} ds.$$

**Theorem 2.4.** [39] Consider the following commensurate fractional-order system:

$$\frac{d^\alpha x}{dt^\alpha} = f(x), \quad x(0) = x_0,$$

with  $0 < \alpha < 1$  and  $x \in \mathbb{R}^n$ . The equilibrium points of the above system are calculated by solving the equation:  $f(x) = 0$ . These points are locally asymptotically stable if all eigenvalues  $\lambda_i$  of the Jacobian matrix evaluated at the equilibrium points satisfy the inequality:  $|\arg(\lambda_i)| > \frac{\alpha\pi}{2}$ .

### 3. QUALITATIVE ANALYSIS OF SYSTEM (1.2)

**3.1. The reproduction number and the existence of equilibriums.** The basic reproduction number  $R_0$  means that the expected number of new infections generated by a single infected person during his/her entire period of infectiousness when introduced in a completely susceptible population, which can be derived by using the next generation operator technique [40, 41]. From this method, we get the basic reproduction number of system (1.2) as follows

$$R_0 = \rho(FV^{-1}) = \frac{\beta(\mu + \rho + \gamma\rho_1)(\delta\rho_2V^0 + \delta S^0 + \mu(1-l)S^0)}{(\mu + \delta)(\mu + \rho)(\mu + \varepsilon) + (\mu + \delta + \rho)\mu\gamma},$$

where  $\rho(\cdot)$  represents the spectral radius. The matrixes  $F$ , and  $V$  are given by

$$F = \begin{pmatrix} 0 & \beta(lS^0 + \rho_2V^0) & \rho_1\beta(lS^0 + \rho_2V^0) \\ 0 & (1-l)\beta S^0 & (1-l)\rho_1\beta S^0 \\ 0 & 0 & 0 \end{pmatrix}, \quad V = \begin{pmatrix} \mu + \delta & 0 & -\rho \\ -\delta & b_2 & \mu + \varepsilon + \gamma \\ 0 & -\gamma & \mu + \rho \end{pmatrix},$$

where  $S^0 = \frac{\Lambda}{\mu + p}$ , and  $V^0 = \frac{\Lambda p}{\mu(\mu + p)}$ .

The equilibriums of model (1.2) are obtained by solving the algebraic system

$$\begin{cases} \Lambda - \frac{\beta SI}{1 + \theta_1 I} - \rho_1 \beta ST - (\mu + p)S = 0, \\ pS - \frac{\rho_2 \beta VI}{1 + \theta_2 I} - \rho_1 \rho_2 \beta VT - \mu V = 0, \\ \frac{l\beta SI}{1 + \theta_1 I} + \rho_1 l\beta ST + \frac{\rho_2 \beta VI}{1 + \theta_2 I} + \rho_1 \rho_2 \beta VT - (\mu + \delta)L + \rho T = 0, \\ \frac{(1-l)\beta SI}{1 + \theta_1 I} + (1-l)\rho_1 \beta ST + \delta L - (\mu + \varepsilon + \gamma)I = 0, \\ \gamma I - (\mu + \rho)T = 0. \end{cases}$$

By simple calculation, we obtain two equilibriums of system (1.2), namely,

- (1) disease-free equilibrium  $E_0 = (S^0, V^0, 0, 0, 0)$ ;
- (2) endemic equilibrium  $E^* = (S^*, V^*, L^*, I^*, T^*)$ , where

$$S^* = \frac{\Lambda(1 + \theta_1 I^*)}{\beta I^* + (1 + \theta_1 I^*)(\rho_1 \beta \frac{\gamma}{\mu + \rho} I^* + \mu + p)}, \quad V^* = \frac{pS^*(1 + \theta_2 I^*)}{\rho_2 \beta I^* + (1 + \theta_2 I^*)(\rho_1 \rho_2 \beta T^* + \mu)},$$

$$L^* = \frac{1}{\mu + \delta} \left( \frac{l\beta S^* I^*}{1 + \theta_1 I^*} + \rho_1 l\beta S^* T^* + \frac{\rho_2 \beta V^* I^*}{1 + \theta_2 I^*} + \rho_1 \rho_2 \beta V^* T^* + \rho T^* \right), \quad T^* = \frac{\gamma}{\mu + \rho} I^*,$$

and  $I^*$  is determined by the following equation

$$A_1 I^4 + A_2 I^3 + A_3 I^2 + A_4 I + A_5 = 0, \tag{3.1}$$

where

$$\begin{aligned}
A_1 &= \theta_1 \theta_2 \rho_1^2 \rho_2 \beta^2 \left( \frac{\gamma}{\mu + \rho} \right)^2 \frac{1}{\mu(\mu + p)} > 0, \\
A_2 &= -\frac{\theta_1 \theta_2 \rho_1^2 \rho_2 \beta^2 \gamma^2 \Lambda [\mu(1-l) + \delta]}{\mu(\mu + p)(\mu + \rho)[(\mu + \delta)(\mu + \rho)(\mu + \varepsilon) + (\mu + \delta + \rho)\mu\gamma]} \\
&\quad - \frac{\rho_1 \beta \gamma \theta_1}{\mu(\mu + p)(\mu + \rho)} \left( \rho_2 \beta + \frac{\rho_1 \rho_2 \beta \gamma}{\mu + \rho} + \mu \theta_2 \right) \\
&\quad + \frac{\rho_1 \beta \gamma \rho_2 \delta \theta_2}{\mu(\mu + p)(\mu + \rho)} \left[ \beta + \frac{\rho_1 \beta \gamma}{\mu + \rho} + \theta_1(\mu + p) \right], \\
A_3 &= -\frac{\rho_1 \beta \Lambda \gamma [\mu(1-l) + \delta] \left[ \rho_2 \beta \theta_2 \left( 1 + \frac{\rho_1 \gamma}{\mu + \rho} \right) + \theta_1 \left( \rho_2 \beta + \frac{\rho_1 \rho_2 \beta \gamma}{\mu + \rho} + \mu \theta_2 \right) \right]}{\mu(\mu + p)[(\mu + \delta)(\mu + \rho)(\mu + \varepsilon) + (\mu + \delta + \rho)\mu\gamma]} \\
&\quad - \frac{\theta_1 \theta_2 \rho_1 \rho_2 \beta \rho \Lambda \gamma \delta}{\theta_1 \theta_2 \rho_1 \rho_2 \beta \rho \Lambda \gamma \delta} \\
&\quad - \frac{\mu(\mu + p)[(\mu + \delta)(\mu + \rho)(\mu + \varepsilon) + (\mu + \delta + \rho)\mu\gamma]}{\mu(\mu + p)} \\
&\quad + \frac{1}{\mu(\mu + p)} \left[ \beta + \rho_1 \frac{\beta \gamma}{\mu + \rho} + \theta_1(\mu + p) \right] \left( \rho_2 \beta + \rho_1 \rho_2 \frac{\beta \gamma}{\mu + \rho} + \mu \theta_2 \right) \\
&\quad + \frac{1}{\mu(\mu + p)} \left[ \mu \theta_1 \rho_1 \frac{\beta \gamma}{\mu + \rho} + \theta_2 \rho_1 \rho_2 \frac{\beta \gamma}{\mu + \rho} (\mu + p) \right], \\
A_4 &= -\frac{\beta \Lambda [\mu(1-l) + \delta] \left( \rho_2 \beta + \rho_1 \rho_2 \frac{\beta \gamma}{\mu + \rho} + \mu \theta_2 \right) (\mu + \rho + \rho_1 \gamma)}{\mu(\mu + p)[(\mu + \delta)(\mu + \rho)(\mu + \varepsilon) + (\mu + \delta + \rho)\mu\gamma]} \\
&\quad - \frac{\beta \Lambda \{ \theta_1 \mu \rho_1 \gamma [\mu(1-l) + \delta] + \theta_1 \rho_2 p \delta (\mu + \rho) + \rho_1 \rho_2 p \gamma \delta (\theta_1 + \theta_2) \}}{\mu(\mu + p)[(\mu + \delta)(\mu + \rho)(\mu + \varepsilon) + (\mu + \delta + \rho)\mu\gamma]} \\
&\quad + \frac{1}{\mu(\mu + p)} \left\{ \mu \left( \beta + \rho_1 \frac{\beta \gamma}{\mu + \rho} + \theta_1(\mu + p) \right) + (\mu + p) \left( \rho_2 \beta + \frac{\rho_1 \rho_2 \beta \gamma}{\mu + \rho} + \mu \theta_2 \right) \right\}, \\
A_5 &= 1 - R_0.
\end{aligned}$$

If  $R_0 > 1$ , then Descartes rule of sign ensures that the above Eq.(3.1) possesses at least one positive root.

**3.2. The stability of the equilibriums.** The Jacobian matrix of system (1.2) reads as

$$J = \begin{pmatrix} a_{11} & 0 & 0 & a_{14} & -\rho_1 \beta S \\ p & a_{22} & 0 & a_{24} & -\rho_1 \rho_2 \beta V \\ a_{31} & a_{32} & -(\mu + \delta) & a_{34} & a_{35} \\ a_{41} & 0 & \delta & a_{44} & (1-l)\rho_1 \beta S \\ 0 & 0 & 0 & \gamma & -(\mu + \rho) \end{pmatrix},$$

where

$$\begin{aligned}
a_{11} &= -\frac{\beta I}{1 + \theta_1 I} - \rho_1 \beta T - (\mu + p), & a_{14} &= -\frac{\beta S}{(1 + \theta_1 I)^2}, \\
a_{22} &= -\frac{\rho_2 \beta I}{1 + \theta_2 I} - \rho_1 \rho_2 \beta T - \mu, & a_{24} &= -\frac{\rho_2 \beta V}{(1 + \theta_2 I)^2}, \\
a_{31} &= \frac{l \beta I}{1 + \theta_1 I} + \rho_1 l \beta T, & a_{32} &= \frac{\rho_2 \beta I}{1 + \theta_2 I} + \rho_1 \rho_2 \beta T, \\
a_{34} &= \frac{l \beta S}{(1 + \theta_1 I)^2} + \frac{\rho_2 \beta V}{(1 + \theta_2 I)^2}, & a_{35} &= \rho_1 l \beta S + \rho_1 \rho_2 \beta V + \rho, \\
a_{41} &= \frac{(1-l)\beta I}{1 + \theta_1 I} + (1-l)\rho_1 \beta T, & a_{44} &= \frac{(1-l)\beta S}{(1 + \theta_1 I)^2} - (\mu + \varepsilon + \gamma).
\end{aligned}$$

The Jacobian matrix of system (1.2) at equilibrium point  $E_0$  is

$$J(E_0) = \begin{pmatrix} -(\mu + p) & 0 & 0 & -\beta S^0 & -\rho_1 \beta S^0 \\ p & -\mu & 0 & -\rho_2 \beta V^0 & -\rho_1 \rho_2 \beta V^0 \\ 0 & 0 & -(\mu + \delta) & l\beta S^0 + \rho_2 \beta V^0 & \rho_1(l\beta S^0 + \rho_2 \beta V^0) + \rho \\ 0 & 0 & \delta & (1-l)\beta S^0 - (\mu + \varepsilon + \gamma) & (1-l)\rho_1 \beta S^0 \\ 0 & 0 & 0 & \gamma & -(\mu + \rho) \end{pmatrix}.$$

The corresponding characteristic equation of the above matrix is

$$(\lambda + \mu + p)(\lambda + \mu)(\lambda^3 + a_1\lambda^2 + a_2\lambda + a_3) = 0.$$

It is obvious that two eigenvalues can be directly obtained:  $\lambda_1 = -(\mu + p) < 0$ ,  $\lambda_2 = -\mu < 0$ , and the other eigenvalues are determined by the following equation

$$Q(\lambda) = \lambda^3 + a_1\lambda^2 + a_2\lambda + a_3 = 0,$$

where

$$\begin{aligned} a_1 &= (\mu + \rho) + (\mu + \delta) + (\mu + \varepsilon + \gamma) - (1-l)\beta S^0, \\ a_2 &= -(2\mu + \rho + \delta)[(1-l)\beta S^0 - (\mu + \varepsilon + \gamma)] - (1-l)\gamma\rho_1\beta S^0 \\ &\quad - \delta\beta(lS^0 + \rho_2V_0) + (\mu + \rho)(\mu + \delta), \\ a_3 &= 1 - R_0. \end{aligned}$$

Let  $D(Q)$  denote the discriminant of a polynomial  $Q(\lambda) = \lambda^3 + a_1\lambda^2 + a_2\lambda + a_3$ . From [42, Proposition 1], we get

$$D(Q) = 18a_1a_2a_3 + (a_1a_2)^2 - 4a_3a_1^3 - 4a_2^3 - 27a_3^3.$$

Then the following properties can be obtained from [42, Proposition 1].

**Proposition 3.1.** *The equilibrium  $E_0$  is asymptotically stable if one of the following conditions holds for polynomial  $Q$  and  $D(Q)$ :*

- (1)  $D(Q) > 0$ ,  $a_1 > 0$ ,  $a_3 > 0$  and  $a_1a_2 > a_3$ ,
- (2)  $D(Q) < 0$ ,  $a_1 \geq 0$ ,  $a_2 \geq 0$ ,  $a_3 \geq 0$  and  $\alpha < \frac{2}{3}$ ,
- (3)  $D(Q) < 0$ ,  $a_1 > 0$ ,  $a_2 > 0$ ,  $a_1a_2 = a_3$  and  $\alpha \in (0, 1)$ .

Next, we discuss the global asymptotic stability of the disease-free equilibrium.

**Theorem 3.2.** *If  $R_0 \leq 1$ , then the disease-free equilibrium  $E_0$  of system (1.2) is global asymptotically stable within  $\Omega$ .*

*Proof.* Consider the following Lyapunov function

$$V = \delta L + (\mu + \delta)I + AT,$$

where  $A = \frac{\delta\rho_1 l\beta S^0 + \rho_1\rho_2\beta V^0 + \rho + (\mu + \delta)(1-l)\rho_1\beta S^0}{\mu + \rho}$ . Then,

$$\begin{aligned}
& D_t^\alpha V|_{(1,2)} \\
&= \delta \left[ \frac{l\beta SI}{1 + \theta_1 I} + \rho_1 l\beta ST + \frac{\rho_2\beta VI}{1 + \theta_2 I} + \rho_1\rho_2\beta VT - (\mu + \delta)L + \rho T \right] \\
&\quad + (\mu + \delta) \left[ \frac{(1-l)\beta SI}{1 + \theta_1 I} + (1-l)\rho_1\beta ST + \delta L - (\mu + \varepsilon + \gamma)I \right] + A[\gamma I - (\mu + \rho)T] \\
&\leq \delta [l\beta SI + \rho_1 l\beta ST + \rho_2\beta VI + \rho_1\rho_2\beta VT - (\mu + \delta)L + \rho T] \\
&\quad + (\mu + \delta) [(1-l)\beta SI + (1-l)\rho_1\beta ST + \delta L - (\mu + \varepsilon + \gamma)I] + A[\gamma I - (\mu + \rho)T] \\
&\leq [\delta l\beta S^0 + \delta\rho_2\beta V^0 + (\mu + \delta)(1-l)\beta S^0 - (\mu + \delta + \gamma) + A\gamma] I \\
&\quad + [\delta\rho_1 l\beta S^0 + \rho_1\rho_2\beta V^0 + \rho + (\mu + \delta)(1-l)\rho_1\beta S^0 - A(\mu + \rho)] T \\
&= \frac{[\delta l\beta S^0 + \delta\rho_2\beta V^0 + (\mu + \delta)(1-l)\beta S^0 - (\mu + \delta + \gamma) + A\gamma] I}{(\mu + \delta)(\mu + \rho)(\mu + \varepsilon) + \mu\gamma(\mu + \delta + \rho)} (R_0 - 1)I.
\end{aligned}$$

If  $R_0 \leq 1$ , then  $D_t^\alpha V|_{(1,2)} \leq 0$ . Further, it is obvious that the invariant set of  $\{(S, V, L, I, T) \in \Omega : D_t^\alpha V|_{(1,2)} = 0\}$  is the singleton  $\{E_0\}$ . Therefore, it follows from LaSalle invariance principle that  $E_0$  is globally stable if  $R_0 \leq 1$ .  $\square$

Now let us study the stability of the endemic equilibrium. The Jacobian matrix at equilibrium  $E^*$  is

$$J = \begin{pmatrix} b_{11} & 0 & 0 & b_{14} & -\rho_1\beta S^* \\ p & b_{22} & 0 & b_{24} & -\rho_1\rho_2\beta V^* \\ b_{31} & b_{32} & -(\mu + \delta) & b_{34} & b_{35} \\ b_{41} & 0 & \delta & b_{44} & (1-l)\rho_1\beta S^* \\ 0 & 0 & 0 & \gamma & -(\mu + \rho), \end{pmatrix}$$

where

$$\begin{aligned}
b_{11} &= -\frac{\beta I^*}{1 + \theta_1 I^*} - \rho_1\beta T^* - (\mu + p), & b_{14} &= -\frac{\beta S^*}{(1 + \theta_1 I^*)^2}, \\
b_{22} &= -\frac{\rho_2\beta I^*}{1 + \theta_2 I^*} - \rho_1\rho_2\beta T^* - \mu, & b_{24} &= -\frac{\rho_2\beta V^*}{(1 + \theta_2 I^*)^2}, \\
b_{31} &= \frac{l\beta I^*}{1 + \theta_1 I^*} + \rho_1 l\beta T^*, & b_{32} &= \frac{\rho_2\beta I^*}{1 + \theta_2 I^*} + \rho_1\rho_2\beta T^*, \\
b_{34} &= \frac{l\beta S^*}{(1 + \theta_1 I^*)^2} + \frac{\rho_2\beta V^*}{(1 + \theta_2 I^*)^2}, & b_{35} &= \rho_1 l\beta S^* + \rho_1\rho_2\beta V^* + \rho, \\
b_{41} &= \frac{(1-l)\beta I^*}{1 + \theta_1 I^*} + (1-l)\rho_1\beta T^*, & b_{44} &= \frac{(1-l)\beta S^*}{(1 + \theta_1 I^*)^2} - (\mu + \varepsilon + \gamma).
\end{aligned}$$

and the corresponding characteristic equation is

$$\lambda^5 + B_1\lambda^4 + B_2\lambda^3 + B_3\lambda^2 + B_4\lambda + B_5 = 0, \tag{3.2}$$



where

$$\begin{aligned}
B_1 &= \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} + \frac{pS^*}{V^*} + \frac{\Lambda}{S^*} + \mu + \delta + \rho - \varepsilon - \gamma, \\
B_2 &= (\mu + \rho) \left[ \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} - (\mu + \varepsilon + \gamma) \right] - (1-l)\rho_1 \beta \gamma S^* \\
&\quad + (\mu + \delta) \left[ \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} + \rho - \varepsilon - \gamma \right] \\
&\quad - \delta \beta \left[ \frac{lS^*}{(1+\theta_1 I^*)^2} + \frac{\rho_2 V^*}{(1+\theta_2 I^*)^2} \right] + \frac{(1-l)\beta^2 S^*}{(1+\theta_1 I^*)^2} \left( \frac{I^*}{1+\theta_1 I^*} + \rho_1 T^* \right) + \frac{p\Lambda}{V^*} \\
&\quad + \left( \frac{pS^*}{V^*} + \frac{\Lambda}{S^*} \right) \left[ \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} + \mu + \delta + \rho - \varepsilon - \gamma \right], \\
B_3 &= \left( \mu + \delta + \frac{pS^*}{V^*} \right) \left\{ (\mu + \rho) \left[ \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} - (\mu + \varepsilon + \gamma) \right] - (1-l)\rho_1 \beta \gamma S^* \right\} \\
&\quad - \delta \beta \left( \mu + \rho + \frac{pS^*}{V^*} \right) \left[ \frac{lS^*}{(1+\theta_1 I^*)^2} + \frac{\rho_2 V^*}{(1+\theta_2 I^*)^2} \right] - \delta \rho_1 \beta \gamma (lS^* + \rho_2 V^*) - \delta \rho \\
&\quad + \frac{pS^*}{V^*} (\mu + \delta) \left[ \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} + \rho - \varepsilon - \gamma \right] + \frac{\delta \rho_2^2 \beta^2 V^*}{(1+\theta_2 I^*)^2} \left( \frac{I^*}{1+\theta_2 I^*} + \rho_1 T^* \right) \\
&\quad + \beta^2 S^* \left( \frac{I^*}{1+\theta_1 I^*} + \rho_1 T^* \right) \left[ \frac{\delta l + (1-l)(\mu + \delta + \frac{pS^*}{V^*})}{(1+\theta_1 I^*)^2} \right. \\
&\quad \left. + (1-l) \left( \frac{\mu + \rho}{(1+\theta_1 I^*)^2} + \rho_1 \gamma \right) \right], \\
B_4 &= \left[ \frac{pS^*}{V^*} (\mu + \delta) + \frac{\Lambda}{S^*} \right] \left\{ (\mu + \rho) \left[ \frac{(1-l)\beta S}{(1+\theta_1 I^*)^2} - (\mu + \varepsilon + \gamma) \right] - (1-l)\rho_1 \beta \gamma S \right\} \\
&\quad - \delta \beta \left[ \frac{lS^*}{(1+\theta_1 I^*)^2} + \frac{\rho_2 V^*}{(1+\theta_2 I^*)^2} \right] \left[ \frac{pS^*}{V^*} (\mu + \rho) + \frac{\Lambda}{S^*} \right] \\
&\quad - \frac{\delta pS^*}{V^*} [\rho_1 \beta \gamma (lS^* + \rho_2 V^*) - \rho] + \frac{\Lambda(\mu + \delta)}{S^*} \left[ \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} + \rho - \varepsilon - \gamma \right] \\
&\quad + \delta \rho_2 \beta^2 \left( \frac{I^*}{1+\theta_2 I^*} + \rho_1 T^* \right) \left[ \frac{\rho_2 V^*}{(1+\theta_2 I^*)^2} + \frac{pS^*}{(1+\theta_1 I^*)^2} \right] \\
&\quad + \beta^2 S^* \left( \frac{I^*}{1+\theta_2 I^*} + \rho_1 T^* \right) \left[ \frac{\mu + \rho}{(1+\theta_1 I^*)^2} + \rho_1 \gamma \right] \left[ \delta l + (1-l) \left( \mu + \delta + \frac{pS^*}{V^*} \right) \right] \\
&\quad + \frac{\Lambda p}{V^*} + \frac{p\beta^2 (S^*)^2}{(1+\theta_1 I^*)^2} \left( \frac{I^*}{1+\theta_1 I^*} + \rho_1 T^* \right) [(1-l)\mu + \delta], \\
B_5 &= \frac{\Lambda p}{V^*} \left\{ (\mu + \rho)(\mu + \delta) \left[ \frac{(1-l)\beta S^*}{(1+\theta_1 I^*)^2} - (\mu + \varepsilon + \gamma) \right] - (\mu + \delta)(1-l)\rho_1 \beta \gamma S^* \right\} \\
&\quad + \frac{\delta \Lambda p}{V^*} \left\{ \beta(\mu + \rho) \left[ \frac{lS^*}{(1+\theta_1 I^*)^2} + \frac{\rho_2 V^*}{(1+\theta_2 I^*)^2} \right] - \rho_1 \beta \gamma (lS^* + \rho_2 V^*) - \rho \right\} \\
&\quad + \delta \rho_2 \beta^2 \left( \frac{I^*}{1+\theta_2 I^*} + \rho_1 T^* \right) \left\{ pS^* \left[ \frac{\mu + \rho}{(1+\theta_1 I^*)^2} + \rho_1 \gamma \right] \right. \\
&\quad \left. + \frac{\Lambda \rho_2 V^*}{S^*} \left[ \frac{\mu + \rho}{(1+\theta_2 I^*)^2} + \rho_1 \gamma \right] \right\} \\
&\quad + \frac{p\beta^2 (S^*)^2}{V^*} \left( \frac{I^*}{1+\theta_1 I^*} + \rho_1 T^* \right) [(1-l)\mu + \delta] \left[ \frac{\mu + \rho}{(1+\theta_1 I^*)^2} + \rho_1 \gamma \right].
\end{aligned}$$

**Proposition 3.3.** *The endemic equilibrium is locally asymptotically stable if all eigenvalues  $\lambda_i$ , ( $i = 1, 3 \dots 5$ ) of characteristic equation (3.2) satisfy the inequality:  $|\arg(\lambda_i)| > \frac{\alpha\pi}{2}$ .*

**3.3. Numerical simulations.** In this section, we will illustrate the existence and stability of the equilibrium of system (1.2) via numerical simulations.




Fig. 1. (a)-(d) are the time series of the system (1.2), which show that the disease-free equilibrium  $E_0$  is global asymptotically stable for  $\alpha = 0.9$ .

**Example 3.4.** For the following set of parameters:  $\beta = 0.00002$  person $^{-1}$ year $^{-1}$ ,  $r_2 = 0.1$ ,  $l = 0.5$ ,  $\delta = 0.368$  year $^{-1}$ ,  $\varepsilon = 0.8$  year $^{-1}$ ,  $p = 0.5$ ,  $\rho = 0.5$  year $^{-1}$ ,  $\gamma = 0.1$ ,  $\theta_1 = 0.2$ ,  $\theta_2 = 0.2$ . In this case,  $R_0 = 0.3141 < 1$ , and the disease-free equilibrium  $E_0 = (S^0, V^0, 0, 0, 0) = (2.778 \times 10^3, 9.922 \times 10^4, 0, 0, 0)$ .

Fig.1 shows that when  $R_0 < 1$ , the equilibrium  $E_0$  is stable for different initial values. This is in accordance with our Theorem 3.2.

**Example 3.5.** For the following set of parameters:  $\beta = 0.0009$  person $^{-1}$ year $^{-1}$ ,  $r_2 = 0.1$ ,  $l = 0.9$ ,  $\delta = 0.368$  year $^{-1}$ ,  $\varepsilon = 0.5$  year $^{-1}$ ,  $p = 0.5$ ,  $\rho = 0.7$  year $^{-1}$ ,  $\gamma = 0.2$ ,  $\theta_1 = 0.2$ ,  $\theta_2 = 0.2$ , and  $\alpha = 1, 0.5, 0.4$ .

From Fig.2, we observe a relaxation process (sub-growth phenomena like sub-diffusion process) when  $0 < \alpha < 1$ . It show that the influence of order cannot be ignored.

**Example 3.6.** For the following set of parameters:  $\beta = 0.00005$  person $^{-1}$ year $^{-1}$ ,  $r_2 = 0.1$ ,  $l = 0.5$ ,  $\delta = 0.368$  year $^{-1}$ ,  $\varepsilon = 0.17$  year $^{-1}$ ,  $p = 0.5$ ,  $\rho = 0.7$  year $^{-1}$ .  $\gamma = 0.1$ .

(1)  $\theta_2 = 0$ , Fig.3.1 shows the dynamics with the initial value  $[S(0), V(0), L(0), I(0), T(0)] = [2000, 1800, 1800, 800, 300]$  for  $\theta_1 = 0, 0.2$ .

(2)  $\theta_1 = 0$ , Fig.3.2 shows the dynamics with the initial value  $[S(0), V(0), L(0), I(0), T(0)] = [2000, 1800, 1800, 800, 300]$  for  $\theta_2 = 0, 0.2$ .

From Fig.3.1 and Fig.3.2, we can see that the parameter  $\theta_1$  and  $\theta_2$  is sensitive to the system.




Fig. 2. (a)-(d) are the time series of the system (1.2), which show that the endemic equilibrium  $E^*$  is local asymptotically stability. (the initial conditions: [2000, 3800, 1800, 800, 300])




Fig. 3.1. (a)-(d) are the time series of system (1.2), which show that the influence of  $\theta_1$  when  $\alpha = 0.9$ . (the initial conditions: [2000, 1800, 1800, 800, 300]).

#### 4. THE OPTIMAL CONTROL PROBLEM

In this section, the initial model is extended to include an optimal control problem for the transmission dynamics of tuberculosis. The goal is to show that time-dependent anti-TB control technologies can be implemented at minimal cost. In order to understand under what circumstances tuberculosis can be controlled or reduced, we implemented the optimal control theory.




Fig. 3.2. (a)-(d) are the time series of system (1.2), which show that the influence of  $\theta_2$  when  $\alpha = 0.9$ . (the initial conditions: [2000, 1800, 1800, 800, 300])

Three intervention strategies, called controls, are included in system (1.2). We used  $u_1(t)$  instead of a constant vaccination rate  $p$ ;  $u_2(t)$  was used to replace the fixed rate of successful treatment  $\rho$ ; use  $u_3(t)$  instead of fixed treatment rate  $\gamma$ .

Now, we describe the fractional order equations of the controlled model:

$$\begin{cases} D^\alpha S(t) = \Lambda - \frac{\beta SI}{1 + \theta_1 I} - \rho_1 \beta ST - (\mu + u_1(t))S, \\ D^\alpha V(t) = u_1(t)S - \frac{\rho_2 \beta VI}{1 + \theta_2 I} - \rho_1 \rho_2 \beta VT - \mu V, \\ D^\alpha L(t) = \frac{l\beta SI}{1 + \theta_1 I} + \rho_1 l \beta ST + \frac{\rho_2 \beta VI}{1 + \theta_2 I} + \rho_1 \rho_2 \beta VT - (\mu + \delta)L + u_2(t)T, \\ D^\alpha I(t) = \frac{(1-l)\beta SI}{1 + \theta_1 I} + (1-l)\rho_1 \beta ST + \delta L - (\mu + \varepsilon + u_3(t))I, \\ D^\alpha T(t) = u_3(t)I - (\mu + u_2(t))T. \end{cases} \quad (4.1)$$

The optimal control problem of objective (cost) function is given:

$$J(u_1, u_2, u_3) = \int_0^{t_f} [B_1 L(t) + B_2 I(t) + B_3 T(t) + B_4 u_1^4 + B_5 u_2^2 + B_6 u_3^2] dt,$$

$B_i (i = 1, 2, \dots, 6)$  are the weight constants and control measures of infected TB patients. Because of the size and importance of the target feature, they can be selected to balance the cost factor.

We hypothesize that there may be practical limitations on the maximum rate at which individuals can be vaccinated or treated over a period of time and achieve treatment success. We seek optimal controls  $u_1$ ,  $u_2$  and  $u_3$  in  $U$  such that

$$\min J(u_1, u_2, u_3), \quad (4.2)$$

where  $U = \{(u_1, u_2, u_3) | u_i \text{ are Lebesgue integrable, } 0 \leq u_i \leq u_{i \max}, i = 1, 2, 3\}$  is the control set.

**4.1. The existence of an optimal control.** In this section, we will study the sufficient condition for the existence of an optimal control of our system (4.1). We refer to Theorem III 4.1 and its Corollary in [43].

For convenience, let  $\vec{x} = [S, V, L, I, T]^T$  and  $\vec{u} = [u_1, u_2, u_3]^T$  denote the vector of system states variables and controls variables, respectively.

**Theorem 4.1.** *There exists an optimal control  $(u_1^*, u_2^*, u_3^*)$  to problem (4.2).*

*Proof.* From Theorem III 4.1 and its Corollary in [43], we let  $r(t, \vec{x}, \vec{u})$  be the right-hand side of (4.1). We need to proof the following conditions are satisfied:

(1)  $r$  is of class  $C^1$  and there exists a constant  $M$  such that

$$|r(t, 0, 0)| \leq M, \quad |r_{\vec{x}}(t, \vec{x}, \vec{u})| \leq M(1 + |\vec{u}|), \quad |r_{\vec{u}}(t, \vec{x}, \vec{u})| \leq M;$$

(2) The admissible set  $F$  of all solutions to system (4.1) with corresponding control in  $U$  is nonempty;

(3)  $r(t, \vec{x}, \vec{u}) = a(t, \vec{x}) + b(t, \vec{x})\vec{u}$ ;

(4) The control set  $\tilde{U} = [0, u_{1\max}] \times [0, u_{2\max}] \times [0, u_{3\max}]$  is closed, convex and compact;

(5) The integrand of the objective functional is convex in  $\tilde{U}$ .

Denote

$$r(t, \vec{x}, \vec{u}) = \begin{pmatrix} \Lambda - \frac{\beta SI}{1+\theta_1 I} - \rho_1 \beta ST - (\mu + u_1)S \\ u_1 S - \frac{\rho_2 \beta VI}{1+\theta_2 I} - \rho_1 \rho_2 \beta VT - \mu V \\ \frac{l\beta SI}{1+\theta_1 I} + \rho_1 l \beta ST + \frac{\rho_2 \beta VI}{1+\theta_2 I} + \rho_1 \rho_2 \beta VT - (\mu + \delta)L + u_2 T \\ \frac{(1-l)\beta SI}{1+\theta_1 I} + (1-l)\rho_1 \beta ST + \delta L - (\mu + \varepsilon + u_3)I \\ u_3 I - (\mu + u_2)T \end{pmatrix}.$$

Obviously,  $r$  is of class  $C^1$  and  $|r(t, 0, 0)| = \Lambda$ . And we have

$$|r_{\vec{x}}(t, \vec{x}, \vec{u})| = \left| \begin{pmatrix} c_{11} & 0 & 0 & c_{14} & -\rho_1 \beta S \\ p & c_{22} & 0 & c_{24} & -\rho_1 \rho_2 \beta V \\ c_{31} & a_{32} & -(\mu + \delta) & c_{34} & c_{35} \\ c_{41} & 0 & \delta & c_{44} & (1-l)\rho_1 \beta S \\ 0 & 0 & 0 & \gamma & -(\mu + \rho) \end{pmatrix} \right|,$$

where

$$\begin{aligned} c_{11} &= -\frac{\beta I}{1+\theta_1 I} - \rho_1 \beta T - (\mu + p), & c_{14} &= -\frac{\beta S}{(1+\theta_1 I)^2}, \\ c_{22} &= -\frac{\rho_2 \beta I}{1+\theta_2 I} - \rho_1 \rho_2 \beta T - \mu, & c_{24} &= -\frac{\rho_2 \beta V}{(1+\theta_2 I)^2}, \\ c_{31} &= \frac{l\beta I}{1+\theta_1 I} + \rho_1 l \beta T, & c_{32} &= \frac{\rho_2 \beta I}{1+\theta_2 I} + \rho_1 \rho_2 \beta T, \\ c_{34} &= \frac{l\beta S}{(1+\theta_1 I)^2} + \frac{\rho_2 \beta V}{(1+\theta_2 I)^2}, & c_{35} &= \rho_1 l \beta S + \rho_1 \rho_2 \beta V + \rho, \\ c_{41} &= \frac{(1-l)\beta I}{1+\theta_1 I} + (1-l)\rho_1 \beta T, & c_{44} &= \frac{(1-l)\beta S}{(1+\theta_1 I)^2} - (\mu + \varepsilon + \gamma). \end{aligned}$$

and

$$|r_{\vec{u}}(t, \vec{x}, \vec{u})| = \left| \begin{pmatrix} -S & 0 & 0 \\ S & 0 & 0 \\ 0 & T & 0 \\ 0 & 0 & -I \\ 0 & -T & I \end{pmatrix} \right|.$$

Since  $S, V, L, I, T$  are bounded, then condition (1) holds, which further implies that condition (2) holds.

In addition, through simple calculation shows that condition (3) satisfies. And obviously condition (4) is satisfied. According to Theorem 3.1 in [44], condition (5) is satisfied.  $\square$

**4.2. Characterization of an optimal control.** Next, we obtain the necessary conditions to utilize Pontryagin's Maximum Principle [45, 46] and find the optimal solution.

Note that the Hamiltonian function for our problem is given by:

$$\begin{aligned} & H(S, V, L, I, T, u_1, u_2, u_3, \lambda) \\ &= B_1 L(t) + B_2 I(t) + B_3 T(t) + B_4 u_1^4 + B_5 u_2^2 + B_6 u_3^2 \\ &+ \lambda_1 \left[ \Lambda - \frac{\beta SI}{1 + \theta_1 I} - \rho_1 \beta ST - (\mu + u_1) S \right] \\ &+ \lambda_2 \left[ u_1 S - \frac{\rho_2 \beta VI}{1 + \theta_2 I} - \rho_1 \rho_2 \beta VT - \mu V \right] \\ &+ \lambda_3 \left[ \frac{l \beta SI}{1 + \theta_1 I} + \rho_1 l \beta ST + \frac{\rho_2 \beta VI}{1 + \theta_2 I} + \rho_1 \rho_2 \beta VT - (\mu + \delta) L + u_2 T \right] \\ &+ \lambda_4 \left[ \frac{(1-l) \beta SI}{1 + \theta_1 I} + (1-l) \rho_1 \beta ST + \delta L - (\mu + \varepsilon + u_3) I \right] \\ &+ \lambda_5 [u_3 I - (\mu + u_2) T], \end{aligned}$$

where,  $\lambda = (\lambda_1, \lambda_2, \lambda_3, \lambda_4, \lambda_5)$  is known as adjoint variable.

**Theorem 4.2.** *Let  $S^*, V^*, L^*, I^*, T^*$  be optimal state solutions with associated optimal control variable  $(u_1^*, u_2^*, u_3^*)$  for the optimal control problem (4.1)-(4.2). Then there exist adjoint variables  $\lambda_i$ , for  $i = 1, 2, \dots, 5$ , satisfying*

$$\begin{cases} \frac{d\lambda_1}{dt} = \frac{\lambda_1 \beta I}{1 + \theta_1 I} + \lambda_1 \rho_1 \beta T + \lambda_1 (\mu + u_1) - \lambda_2 u_1 - \frac{\lambda_3 l \beta I}{1 + \theta_1 I} - \lambda_3 \rho_1 l \beta T - \frac{\lambda_4 (1-l) \beta I}{1 + \theta_1 I} - \lambda_4 (1-l) \rho_1 \beta I, \\ \frac{d\lambda_2}{dt} = \frac{\lambda_2 \rho_2 \beta I}{1 + \theta_2 I} + \lambda_2 \rho_1 \rho_2 \beta T + \lambda_2 \mu - \frac{\lambda_3 \rho_2 \beta I}{1 + \theta_2 I} - \lambda_3 \rho_1 \rho_2 \beta T, \\ \frac{d\lambda_3}{dt} = -B_1 + \lambda_3 (\mu + \delta) - \lambda_4 \delta, \\ \frac{d\lambda_4}{dt} = -B_2 + \frac{\lambda_1 \beta S}{(1 + \theta_1 I)^2} + \frac{\lambda_2 \rho_2 \beta V}{(1 + \theta_2 I)^2} - \frac{\lambda_3 l \beta S}{(1 + \theta_1 I)^2} - \frac{\lambda_3 \rho_2 \beta V}{(1 + \theta_2 I)^2} - \frac{\lambda_4 (1-l) \beta S}{(1 + \theta_1 I)^2} + \lambda_4 (\mu + \varepsilon + u_3) - \lambda_5 u_3, \\ \frac{d\lambda_5}{dt} = -B_3 + \lambda_1 \rho_1 \beta S + \lambda_2 \rho_1 \rho_2 \beta V - \lambda_3 \rho_1 l \beta S - \lambda_3 \rho_1 \rho_2 \beta V \\ \quad - \lambda_3 u_2 - \lambda_4 (1-l) \rho_1 \beta S + \lambda_5 (\mu + u_2). \end{cases}$$

with transversal conditions (or boundary conditions)

$$\lambda_i(t_f) = 0, \quad i = 1, 2, \dots, 5.$$

Furthermore, optimal control  $u_i^*$ , ( $i = 1, 2, 3$ ) is given by

$$\begin{aligned} u_1^* &= \min \left\{ \max \left\{ 0, \left( \frac{(\lambda_1 - \lambda_2)S^*}{4B_4} \right)^{\frac{1}{3}} \right\}, u_{1\max} \right\}, \\ u_2^* &= \min \left\{ \max \left\{ 0, \frac{(\lambda_5 - \lambda_3)T^*}{2B_5} \right\}, u_{2\max} \right\}, \\ u_3^* &= \min \left\{ \max \left\{ 0, \frac{(\lambda_4 - \lambda_5)T^*}{2B_6} \right\}, u_{3\max} \right\}. \end{aligned} \quad (4.3)$$

*Proof.* In order to determine adjoint equations and transversal conditions, we use Hamiltonian. The adjoint system can be derived from Pontryagin's Maximum Principle

$$\begin{cases} \frac{d\lambda_1}{dt} = -\frac{\partial H}{\partial S}, \\ \frac{d\lambda_2}{dt} = -\frac{\partial H}{\partial V}, \\ \frac{d\lambda_3}{dt} = -\frac{\partial H}{\partial L}, \\ \frac{d\lambda_4}{dt} = -\frac{\partial H}{\partial I}, \\ \frac{d\lambda_5}{dt} = -\frac{\partial H}{\partial T}, \end{cases}$$

with  $\lambda_i(t_f) = 0$ . Let  $\frac{\partial H}{\partial u_1} = \frac{\partial H}{\partial u_2} = \frac{\partial H}{\partial u_3} = 0$ , we can get the formula of Eq.(4.3).  $\square$

**4.3. Numerical simulations.** In this section, we discuss the numerical simulation of model (4.1) with the cost function of the optimal control strategy.

**Example 4.3.** For the following set of parameters:  $\beta = 0.003 \text{ person}^{-1}\text{year}^{-1}$ ,  $r_2 = 0.2$ ,  $l = 0.9$ ,  $\delta = 0.00368 \text{ year}^{-1}$ ,  $\varepsilon = 0.17 \text{ year}^{-1}$ ,  $\theta_1 = 0.2$ ,  $\theta_2 = 0.2$ .

As expected, the results shown in Fig.4(c) clearly indicate that the optimal control results are very effective in the control of patients infected with latent TB; In Fig.4(e), the number of people receiving treatment dropped sharply in the first four years, and then dropped sharply, this is due to treatment that controls  $u_3$  to zero after 4 years. And Fig.4 shows a slight increase in the intervention strategy after 4 years.

**Example 4.4.** For the following set of parameters:  $\beta = 0.003 \text{ person}^{-1}\text{year}^{-1}$ ,  $r_2 = 0.2$ ,  $l = 0.9$ ,  $\delta = 0.00368 \text{ year}^{-1}$ ,  $\varepsilon = 0.17 \text{ year}^{-1}$ ,  $\theta_1 = 0.2$ ,  $\theta_2 = 0.2$ .

Fig.5 shows that the optimal control of system (4.1) is bang-bang type, and no singular solution is found.

## 5. DISCUSSION

In this paper, a fractional-order tuberculosis model with incomplete treatment was constructed and investigated. In Section 3, we obtained the basic reproduction number  $R_0$ , and the sufficient conditions for the existence and stability of  $E_0$  and  $E^*$ . If  $R_0 < 1$ , then the disease-free equilibrium  $E_0$  of system (1.2) is global asymptotically stable within  $\Omega$ ; If  $R_0 > 1$ , then the endemic equilibrium appears and is local asymptotically stable under certain conditions. In Section 4, we presented the formulation of the optimal control problems, investigated the existence of an optimal control function and derived an optimal system characterizing the optimal control. Through numerical simulation, we have the following results.




Fig. 4. (a)-(e) are the time series of the system (4.1), which show that with and without controls for  $\alpha = 1$  and 0.9, weight constants are  $B_1 = 20, B_2 = 100, B_3 = 200, B_4 = 100, B_5 = 8000, B_6 = 150$ . (the initial conditions: [4500, 3000, 4000, 500, 480]), the red and '—' line:  $\alpha=1$ , with control; the blue and '- -' line:  $\alpha=0.9$  with control; the black and '- · -' line:  $\alpha=1$  without control; the green and '...' line:  $\alpha=0.9$  without control)




Fig. 5. Three optimal control strategies profiles weight constants are  $B_1 = 20, B_2 = 100, B_3 = 200, B_4 = 100, B_5 = 8000, B_6 = 150$  (the initial conditions: [4500, 3000, 4000, 500, 480]).

◇ Fig.1 shows that the disease-free equilibrium  $E_0$  of system (1.2) is indeed globally stable when  $R_0 < 1$ .

◇ Fig.2 shows that the endemic equilibrium  $E^*$  system (1.2) is local globally stable.

◇ Fig.3.1 and Fig.3.2 show that the impact of  $\theta_1$  and  $\theta_2$  on the system is crucial.



◇ Fig.4 shows that vaccination and treatment strategies effectively reduce the spread of TB diseases, especially we can use the lowest cost to obtain the maximum disease control.

**Remark 5.1.** If  $\alpha = 1$  and  $\theta_1 = \theta_2 = 0$ , then system (1.2) degenerates to the model in [31].

In this paper, the effect of time delay is not considered, and we leave it as our future work.

## Acknowledgements

This work was partly supported by National Natural Science Foundation of China (No. 61907027).

## REFERENCES

- [1] World Health Organization, Global tuberculosis control: surveillance, planning, financing, 2005, WHO/HTM/TB/2005.349, Geneve.
- [2] World Health Organization, <https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis>.
- [3] C. Castillo-chavez, B. Song, Dynamical models of tuberculosis and their applications, *Math. Biosci. Eng.* 1 (2004), 361-404.
- [4] Averting HIV and AIDS (2006), AIDS, HIV & Tuberculosis (TB). <http://www.avert.org/tuberc.htm>.
- [5] A.A. Sayers, D.D. Whitt, *Bacterial Pathogenesis: A molecular approach*, Amer. Soc. Microbiology, 2010.
- [6] T.R. Frieden, C.R. Driver, Tuberculosis control: past 10 years and future progress, *Tuberculosis*, 83 (2003), 82-85.
- [7] M.C. Raviglione, Evolution of WHO, policies for tuberculosis control, 1948-2001, *The Lancet*, 359 (2002), 775-780.
- [8] K. Diethelm, A fractional calculus based model for the simulation of an outbreak of dengue fevers, *Nonlinear Dynam.* 71 (2012), 613-619.
- [9] R.L. Magin, Fractional calculus models of complex dynamics in biological tissues, *Comput. Math. Appl.* 59 (2010), 1586-1593.
- [10] J.A. Tenreiro Machado, M.F. Silva, R.S. Barbosa, I.S. Jesus, et al, Some applications of fractional calculus in engineering, *Math. Probl. Eng.* 2010 (2010), 1-34.
- [11] T.A. Yildiz, S. Arshad, D. Baleanu, New observations on optimal cancer treatments for a fractional tumor growth model with and without singular kernel, *Chaos Solitons Fractals* 117 (2018), 226-239.
- [12] Y. Yu, P. Perdikaris, G.E. Karniadakis, Fractional modeling of viscoelasticity in 3D cerebral arteries and aneurysms, *J. Comput. Phys.* 323 (2016), 219-242.
- [13] S.Z. Rida, A.M.A. El-Sayed, A.A.M. Arafa, Effect of bacterial memory dependent growth by using fractional derivatives reaction-diffusion chemotactic model, *J. Stat. Phys.* 140 (2010), 797-811.
- [14] M. S. Asl, M. Javidi, An improved PC scheme for nonlinear fractional differential equations: Error and stability analysis, *J. Comput. Appl. Math.* 324 (2017), 101-117.
- [15] I. Podlubny, *Fractional differential equations*, Academic Press, New York, 1998.
- [16] G.S.F. Frederico, D.F.M. Torres, Fractional conservation laws in optimal control theory, *Nonlinear Dynam.* 53 (2008), 215-222.
- [17] R.L. Magin, O. Abdullah, D. Baleanu, X.J. Zhou, Anomalous diffusion expressed through fractional order differential operators in the Bloch-Torrey equation, *J. Magnetic Resonance*, 190 (2008), 255-270.
- [18] E.H. Doha, A.H. Bhrawy, S.S. Ezz-Eldien, A new Jacobi operational matrix: an application for solving fractional differential equations, *Appl. Math. Model.* 36 (2012), 4931-4943.
- [19] C.I. Muresan, C. Ionescu, S. Folea, R. De Keyser, Fractional order control of unstable processes: the magnetic levitation study case, *Nonlinear Dynam.* 80 (2015), 1761-1772.
- [20] D. Copot, R. De Keyser, E. Derom, M. Ortigueira, C.M. Ionescu, Reducing bias in fractional order impedance estimation for lung function evaluation, *Biomedical Signal Processing and Control*, 39 (2018), 74-80.
- [21] S. Khajanchi, D. Ghosh, The combined effects of optimal control in cancer remission, *Appl. Math. Comput.* 271 (2015), 375-388.
- [22] A. Kumar, P.K. Srivastava, Vaccination and treatment as control interventions in an infectious disease model with their cost optimization, *Commun. Nonlinear Sci. Numer. Simul.* 44 (2017), 334-343.

- [23] J. Lee, J. Kim, Hee-Dae Kwon, Optimal control of an influenza model with seasonal forcing and age dependent transmission rates, *J. Theoret. Biol.* 317 (2013), 310-320.
- [24] I. Zeiler, J. P. Caulkins, D. Grass, G. Tragler, Keeping options open: an optimal control model with trajectories that reach a DNSS point in positive time, *SIAM J. Control Optim.* 48 (2010), 3698-3707.
- [25] Y. Zhou, Y. Liang, J. Wu, An optimal strategy for HIV multitherapy, *J. Comput. Appl. Math.* 263 (2014), 326-337.
- [26] N.H. Sweilam, S.M. Al-Mekhlafi, Optimal control for a fractional tuberculosis infection model including the impact of diabetes and resistant strains, *J. Adv. Res.* 17 (2016), 125-137.
- [27] M. Nategh, B. Agheli, An investigation on an optimal control problem with a fractional constraint in the Riemann-Liouville sense, *Int. J. Adv. Res. Math.* 7 (2016), 10-18.
- [28] E. Jung, S. Lenhart, Z. Feng, Optimal control of treatments in a two-strain tuberculosis model, *Discrete Contin. Dyn. Syst. Ser. B* 2 (2002), 473-482.
- [29] E. Bonyah, Stability analysis and optimal control of a fractional human African trypanosomiasis model, *Chaos Solitons Fractals* 117 (2018), 150-160.
- [30] S. Rosa, Delfim F.M. Torres, Optimal control of a fractional order epidemic model with application to human respiratory syncytial virus infection, *Chaos Solitons Fractals* 117 (2018), 142-149.
- [31] J. Liu, T. Zhang, Global stability for a tuberculosis model, *Math. Comput. Modelling* 54 (2011), 836-845.
- [32] X. Song, Y. Jiang, Analysis of a saturation incidence SVERIS epidemic model with pulse and two time delays, *Appl. Math. Comput.* 214 (2009), 381-390.
- [33] Q. Yang, D. Jiang, N. Shi, C. Ji, The ergodicity and extinction of stochastically perturbed SIR and SEIR epidemic models with saturated incidence, *J. Math. Anal. Appl.* 388 (2012), 248-271.
- [34] M.G.M. Gomes, A. Margheri, G.F. Medley, C. Rebelo, Dynamical behaviour of epidemiological models with sub-optimal immunity and nonlinear incidence, *J. Math Biol.* 51 (2005), 43-61.
- [35] L. Esteva, M. Matlas, A model for vector transmitted disease with saturation incidence, *J. Biol. Syst.* 9 (2001), 235-245.
- [36] Y. Yang, S. Tang, X. Ren, H. Zhao, C. Guo, Global stability and optimal control for a tuberculosis model with vaccination and treatment, *Discrete Contin. Dyn. Syst. Ser. B* 21 (2016), 1009-1022.
- [37] C.J. Silva, D.F.M. Torres, Optimal control for a tuberculosis model with reinfection and post-exposure interventions, *Math. Biosci.* 244 (2013), 154-164.
- [38] P. Rodriguesa, M. G. M. Gomesa, C. Rebelo, Drug resistance in tuberculosis-a reinfection model, *Theoretical Population Biology*, 71 (2007), 196-212.
- [39] I. Petras, *Fractional-Order Nonlinear Systems: Modeling, Analysis and Simulation*, HEP/Springer, London, 2011.
- [40] A. Mclean, S. Blower, Imperfect vaccines and herd immunity to HIV, *Proceedings Biol. Sci.* 253 (1993), 9-13.
- [41] E. H. Elbasha, Global stability of equilibria in a two-sex HPV vaccination system, *Bull. Math. Biol.* 70 (2008), 894-909.
- [42] E. Ahmed, A.M.A. El-Sayed, H.A.A. El-Saka, On some Routh-Hurwitz conditions for fractional order differential equations and their applications in Lorenz, Rossler, Chua and Chen systems, *Phys. Lett. A*, 358 (2006), 1-4.
- [43] W.H. Fleming, R.W. Rishel, *Deterministic and stochastic optimal control*, Springer-Verlag, New York, 1975.
- [44] Da-peng Gao, Nan-jing Huang, Optimal control analysis of a tuberculosis model, *Appl. Math. Model.* 2017.
- [45] S.M. Lenhart, J.T. Workman, *Optimal control applied to biological models*, Chapman & Hall/CRC Math. Comput. Biol. Ser. 2007.
- [46] L.S. Pontryagin, *Mathematical theory of optimal processes*, CRC Press, 1987.